Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Dr Reddy’s Laboratories ( (RDY) ) is now available.
On July 18, 2025, Dr. Reddy’s Laboratories announced that the USFDA completed a GMP and Pre-Approval Inspection at its FTO 11 formulations manufacturing facility in Srikakulam, Andhra Pradesh. The inspection, conducted from July 10 to July 18, resulted in a Form 483 with seven observations, which the company plans to address within the stipulated timeline. This inspection is crucial for the company’s compliance and operational standards, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (RDY) stock is a Buy with a $18.30 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
The overall stock score for Dr Reddy’s Laboratories is solid, driven primarily by strong financial performance, indicating robust growth and stable operations. However, technical analysis suggests bearish momentum, and the valuation indicates limited dividend income potential, which slightly dampens the overall score.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a pharmaceutical company based in Hyderabad, India, known for its formulations, active pharmaceutical ingredients, and biologics. The company focuses on providing affordable and innovative medicines in various therapeutic areas, serving markets across the globe.
Average Trading Volume: 1,649,773
Technical Sentiment Signal: Strong Buy
Current Market Cap: $12.21B
See more insights into RDY stock on TipRanks’ Stock Analysis page.